{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:40Z","timestamp":1792794760224,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TRB Chemedica International SA","id":[{"id":"https:\/\/ror.org\/012pz6314","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren\u2013Lawrence grade 2\u20133 and pain scoring \u22654 (10-cm VAS). Patients were randomized to 6\u2009months of treatment with diacerein 50\u2009mg (n\u2009=\u2009187) once daily for 1\u2009month and twice daily thereafter, or celecoxib 200\u2009mg (n\u2009=\u2009193) once daily. The primary outcome was the change in WOMAC pain score (0\u201350\u2009cm) at 6\u2009months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT\u2013OARSI responder rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was \u201311.1\u2009(\u20090.9) with diacerein (n\u2009=\u2009140) and \u201311.8\u2009(0.9) with celecoxib (n\u2009=\u2009148). The intergroup difference was 0.7 (95% CI: \u22121.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>A multicentre study on the effect of DIacerein on Structure and Symptoms vs Celecoxib in Osteoarthritis is a National Institutes of Health (NCT02688400) and European Clinical Trial Database (2015\u2013002933-23) registered phase III (Canada) or IV (Europe) study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa072","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T15:09:35Z","timestamp":1580483375000},"page":"3858-3868","source":"Crossref","is-referenced-by-count":47,"title":["An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein\n                    <i>vs<\/i>\n                    celecoxib on symptoms in knee osteoarthritis"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-6453","authenticated-orcid":false,"given":"Jean-Pierre","family":"Pelletier","sequence":"first","affiliation":[{"name":"Osteoarthritis Research Unit, University of Montr\u00e9al Hospital Research Centre (CRCHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Raynauld","sequence":"additional","affiliation":[{"name":"Institut de Rhumatologie de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dorais","sequence":"additional","affiliation":[{"name":"StatSciences Inc., Notre-Dame-de-l\u2019\u00cele-Perrot"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Groupe de Recherche en Rhumatologie et Maladies Osseuses, Sainte-Foy, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[{"name":"MEDICAL PLUS s.r.o., Uherske Hradiste, Faculty of Pharmacy, Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Morin","sequence":"additional","affiliation":[{"name":"Centre de Recherche Musculosquelettique, Trois-Rivi\u00e8res, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology and Clinic of Rheumatology, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Paiement","sequence":"additional","affiliation":[{"name":"Imaging Research & Development, ArthroLab Inc, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-383X","authenticated-orcid":false,"given":"Johanne","family":"Martel-Pelletier","sequence":"additional","affiliation":[{"name":"Osteoarthritis Research Unit, University of Montr\u00e9al Hospital Research Centre (CRCHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DISSCO Trial Investigator Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"2020121319242888200_keaa072-B1","first-page":"646","article-title":"Burden of major musculoskeletal conditions","volume":"81","author":"Woolf","year":"2003","journal-title":"Bull World Health Organ"},{"key":"2020121319242888200_keaa072-B2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"2020121319242888200_keaa072-B3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2013.07.003","article-title":"Health economics in the field of osteoarthritis: an expert\u2019s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"43","author":"Hiligsmann","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bmb\/lds038","article-title":"Epidemiology and burden of osteoarthritis","volume":"105","author":"Litwic","year":"2013","journal-title":"Br Med Bull"},{"key":"2020121319242888200_keaa072-B5","doi-asserted-by":"crossref","first-page":"39672","DOI":"10.1038\/srep39672","article-title":"Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"2020121319242888200_keaa072-B6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/2047487315610663","article-title":"Association between osteoarthritis and cardiovascular disease: systematic review and meta-analysis","volume":"23","author":"Hall","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2020121319242888200_keaa072-B7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","article-title":"EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)","volume":"62","author":"Jordan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009","volume":"18","author":"Zhang","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"2020121319242888200_keaa072-B9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2020121319242888200_keaa072-B10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","article-title":"OARSI guidelines for the non-surgical management of knee osteoarthritis","volume":"22","author":"McAlindon","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"2020121319242888200_keaa072-B11","year":"2014"},{"key":"2020121319242888200_keaa072-B12","year":"2011"},{"key":"2020121319242888200_keaa072-B13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"2020121319242888200_keaa072-B14","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.semarthrit.2015.11.009","article-title":"Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys","volume":"45(4 Suppl","author":"Pelletier","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/annrheumdis-2014-206914","article-title":"Paracetamol: not as safe as we thought? A systematic literature review of observational studies","volume":"75","author":"Roberts","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","article-title":"An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"44","author":"Bruyere","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B17","first-page":"CD005117","article-title":"Diacerein for osteoarthritis","volume":"2","author":"Fidelix","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020121319242888200_keaa072-B18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.semarthrit.2015.11.010","article-title":"A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis\u2014from evidence-based medicine to the real-life setting","volume":"45(4 Suppl","author":"Bruyere","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B19","first-page":"337","article-title":"An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)","volume-title":"Semin Arthritis Rheum","author":"Bruy\u00e8re","year":"2019"},{"key":"2020121319242888200_keaa072-B20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/archinte.166.17.1899","article-title":"A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis","volume":"166","author":"Rintelen","year":"2006","journal-title":"Arch Intern Med"},{"key":"2020121319242888200_keaa072-B21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joca.2009.10.006","article-title":"Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Bartels","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"2020121319242888200_keaa072-B22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40264-015-0266-z","article-title":"Benefit\u2013risk assessment of diacerein in the treatment of osteoarthritis","volume":"38","author":"Panova","year":"2015","journal-title":"Drug Saf"},{"key":"2020121319242888200_keaa072-B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40266-016-0347-4","article-title":"Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO","volume":"33","author":"Pavelka","year":"2016","journal-title":"Drugs Aging"},{"key":"2020121319242888200_keaa072-B24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.2042-7158.1983.tb02929.x","article-title":"The influence of rhein on the biosynthesis of prostaglandin-like substances in vitro","volume":"35","author":"Franchi-Micheli","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"2020121319242888200_keaa072-B25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1759720X09359104","article-title":"Effects of diacerein at the molecular level in the osteoarthritis disease process","volume":"2","author":"Martel-Pelletier","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020121319242888200_keaa072-B26","first-page":"10","article-title":"Endoscopic evaluation of diacetylrhein-induced gastric-mucosal lesions","volume":"49","author":"Petrillo","year":"1991","journal-title":"Curr Ther Res Clin Exp"},{"key":"2020121319242888200_keaa072-B27","author":"Mattei","year":"2009"},{"key":"2020121319242888200_keaa072-B28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"Bingham","year":"2007","journal-title":"Rheumatology"},{"key":"2020121319242888200_keaa072-B29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2006.065128","article-title":"Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial","volume":"66","author":"Rother","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.joca.2008.04.009","article-title":"Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis","volume":"16","author":"Bingham","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"2020121319242888200_keaa072-B31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"2020121319242888200_keaa072-B32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/ard.16.4.494","article-title":"Radiological assessment of osteoarthosis","volume":"16","author":"Kellgren","year":"1957","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1185\/030079906X80242","article-title":"Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies","volume":"22","author":"Birbara","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2020121319242888200_keaa072-B35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kep184","article-title":"Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo","volume":"48","author":"Bingham","year":"2009","journal-title":"Rheumatology"},{"key":"2020121319242888200_keaa072-B36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.joca.2009.12.013","article-title":"Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study","volume":"18","author":"Schnitzer","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"2020121319242888200_keaa072-B37","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J Rheumatol"},{"key":"2020121319242888200_keaa072-B38","first-page":"1905","article-title":"ICH Harmonised Tripartite Guideline Topic E9: Statistical principles for clinical trials","volume":"18","year":"1999","journal-title":"Stat Med"},{"key":"2020121319242888200_keaa072-B39","year":"2000"},{"key":"2020121319242888200_keaa072-B40","first-page":"1648","article-title":"Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria","volume":"30","author":"Pham","year":"2003","journal-title":"J Rheumatol"},{"key":"2020121319242888200_keaa072-B41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.1780370413","article-title":"Diacerhein in the treatment of osteoarthritis of the hip","volume":"37","author":"Nguyen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B42","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P","article-title":"Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group","volume":"43","author":"Pelletier","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2020121319242888200_keaa072-B43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1479-8077.2006.00167.x","article-title":"Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China","volume":"9","author":"Zheng","year":"2006","journal-title":"APLAR J Rheumatol"},{"key":"2020121319242888200_keaa072-B44","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10067-009-1225-9","article-title":"Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial","volume":"28","author":"Brahmachari","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2020121319242888200_keaa072-B45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1756-185X.2011.01648.x","article-title":"Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee","volume":"15","author":"Singh","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"2020121319242888200_keaa072-B46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2014-206792","article-title":"Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib","volume":"75","author":"Hochberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2016-210860","article-title":"Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)","volume":"76","author":"Reginster","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020121319242888200_keaa072-B48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40520-018-0911-3","article-title":"Diacerein-containing products: same risk of diarrhoea?","volume":"30","author":"Pelletier","year":"2018","journal-title":"Aging Clin Exp Res"},{"key":"2020121319242888200_keaa072-B49","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020121319242888200_keaa072-B50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.joca.2015.03.005","article-title":"OARSI Clinical Trials Recommendations: design, conduct, and reporting of clinical trials for knee osteoarthritis","volume":"23","author":"McAlindon","year":"2015","journal-title":"Osteoarthritis Cartilage"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3858\/34890152\/keaa072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3858\/34890152\/keaa072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T19:25:17Z","timestamp":1607887517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/12\/3858\/5855643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6,10]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa072","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,6,10]]}}}